The 2026 Peptide Telehealth Landscape: Hims, LifeMD, Henry Meds, Ro, Pep Club, NohoLabs, and How to Pick

In 2026, you can order peptide prescriptions from your phone. A dozen or so telehealth companies have set up online platforms that connect you to a licensed doctor, get you a prescription if you qualify, and ship the medicine to your door.

The six biggest names are Hims & Hers, LifeMD, Henry Meds, Ro, Pep Club, and NohoLabs. Each one works a little differently. Hims and LifeMD sell branded GLP-1 weight-loss drugs (Wegovy, Zepbound) alongside compounded peptides. Henry Meds focuses almost entirely on compounded GLP-1s. Ro leads with weight loss. Pep Club and NohoLabs go deeper on the broader peptide category, including sleep, recovery, hormones, and longevity, with more testing built in.

This piece walks through what each one offers, how they source their medicine, and how to tell them apart. If you are trying to figure out where to buy peptides safely and legally in 2026, this is the map.

Two things happened at once. First, GLP-1 drugs like Ozempic and Wegovy became the biggest drug story in a decade. Weight loss patients wanted access, and traditional insurance often did not cover the prescriptions. Second, the FDA declared the supply of these drugs to be in shortage from 2022 through 2024, which briefly allowed compounding pharmacies to make copies. Telehealth companies stepped in to prescribe and ship both branded and compounded versions.

By 2026, the compounded-GLP-1 window has largely closed. Novo Nordisk and Eli Lilly cut deals with the major telehealth platforms to sell branded Wegovy and Zepbound directly through those platforms at reduced prices. The Medicare GLP-1 Bridge (launched July 1, 2026) added a $50/month copay option for eligible seniors. Meanwhile, a separate wave of non-GLP-1 peptides (BPC-157, TB-500, GHK-Cu, ipamorelin, sermorelin, and others) started moving toward legal 503A compounding after HHS Secretary RFK Jr. announced peptide reclassification in February 2026.

The telehealth platforms live in the middle of all this. They are the retail layer for both the branded GLP-1 supply and the compounded peptide supply that a growing share of Americans are turning to for weight loss, sleep, recovery, and longevity.

Before we get to the differences, the basics that every legit platform provides.

A licensed physician evaluates you online, typically through an intake form followed by a phone or video call. If the doctor decides the prescription is appropriate, they send it to a pharmacy that the platform works with. The pharmacy prepares your medicine and ships it in a temperature-controlled package. Follow-up visits happen through messaging or video calls.

Every platform requires a prescription, which means every platform requires you to meet clinical criteria (BMI thresholds for weight loss, testosterone levels for hormone therapy, and so on). Any platform that promises to ship you injectable peptides without a prescription is either operating outside US law or shipping research-chemical grade product that is not for human use.

Every reputable platform uses either a licensed 503A compounding pharmacy (patient-specific prescriptions) or receives shipments directly from a branded manufacturer (Novo Nordisk, Eli Lilly). No reputable US platform sources active pharmaceutical ingredient from unregulated overseas vendors.

The biggest name, by revenue and stock market attention. Hims went public in 2021 and has grown into a full-service telehealth platform covering weight loss, hair loss, mental health, sexual health, and skincare.

On weight loss: Hims partnered with Novo Nordisk in March 2026 and now sells branded Wegovy injections, Wegovy pills, and Ozempic injections through the platform. The company also owns a California compounding pharmacy (acquired 2025) and sells compounded GLP-1s when a physician decides they are clinically necessary. Pricing: $39 for the first month of GLP-1 subscription, $149/month thereafter for the subscription fee, plus the medication cost.

On peptides more broadly: Hims has stated it plans to expand into the non-GLP-1 peptide category (sleep, recovery, longevity) once the FDA Pharmacy Compounding Advisory Committee (PCAC) votes on July 23-24, 2026 on adding BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, and Epitalon to the 503A bulks list. As of July 2026, Hims does not sell these peptides at scale.

Who Hims is best for: patients who want a mainstream telehealth experience for weight loss with recognized branded drugs at competitive pricing, and who value integration with other services (hair, mental health, dermatology).

The second-largest publicly traded weight-loss telehealth platform. LifeMD offers a similar model to Hims: online physician evaluation, prescription, and shipping. The company has partnerships with major branded manufacturers and also uses 503A compounding pharmacies.

On weight loss: LifeMD sells branded Wegovy, Zepbound, and Foundayo (Lilly's oral GLP-1) alongside compounded semaglutide and tirzepatide when clinically indicated. Membership starts around $75/month and includes lab work and physician visits; medication is billed separately.

On peptides more broadly: LifeMD has begun offering compounded peptides in select categories (testosterone replacement, sexual health) and has signaled expansion into recovery and longevity peptides post-PCAC vote.

Who LifeMD is best for: patients who want a physician-heavy telehealth model with more clinical touchpoints (lab work included) at a mid-tier price point, and who are okay with a slightly less consumer-polished experience than Hims.

Compounding-focused, weight-loss-focused. Henry Meds built its platform around compounded semaglutide and tirzepatide from the start. The company works with 503A compounding pharmacies to ship patient-specific prescriptions.

Pricing: Historically Henry Meds has been the low-price leader on compounded GLP-1s, with monthly costs starting around $250-300/month for compounded semaglutide. As FDA regulations have tightened on compounded GLP-1s in 2026, Henry Meds has adjusted its offering to stay compliant with the narrowing 503A pathway.

On peptides more broadly: Henry Meds primarily focuses on weight loss and is less broad than Hims or LifeMD.

Who Henry Meds is best for: patients who specifically want compounded GLP-1s at the lowest possible price and do not need a broader wellness platform. The trade-off is that as FDA compounding rules narrow, the compounded pathway may become less available.

Important note: with the FDA's proposed permanent exclusion of semaglutide, tirzepatide, and liraglutide from the 503B bulks list (public comment window closed June 29, 2026), the future of high-volume compounded GLP-1 supply is uncertain. Henry Meds may need to shift toward branded supply or a different peptide mix within the next 12 months.

One of the earliest US direct-to-consumer telehealth platforms. Ro built its business initially around erectile dysfunction (Roman brand) and expanded into weight loss, hair loss, fertility, and mental health.

On weight loss: Ro was one of the first platforms to offer compounded GLP-1s and now sells both branded Wegovy and compounded semaglutide. Pricing runs roughly $1,000-1,600/month for branded Wegovy (comparable to what you pay direct at the manufacturer) and less for compounded semaglutide when available.

On peptides more broadly: Ro has not been as aggressive on the broader peptide category as newer platforms like Pep Club and NohoLabs. The company's expansion has focused on the traditional telehealth categories (weight loss, ED, hair).

Who Ro is best for: patients who want a well-established, big-brand telehealth experience with strong customer service and are willing to pay slightly higher prices for the polished platform.

Founded 2025 in San Francisco, $16 million raised. NohoLabs positions itself as a peptide-first health and performance company, with board-certified clinicians, FDA-inspected sourcing, and a concierge-style telehealth experience.

Product focus: NohoLabs leans into the broader peptide category rather than being weight-loss-first. The platform emphasizes sleep, mood, recovery, and performance optimization alongside metabolic and hormonal support. The clinical model is closer to a traditional concierge medicine practice than a mass-market telehealth funnel; patients typically get more clinician time and more individualized protocol design.

Sourcing: FDA-inspected pharmacy partners for the compounded peptide preparations. NohoLabs has stated the sourcing chain runs through licensed 503A pharmacies that meet USP <797> sterile-compounding standards.

Who NohoLabs is best for: patients who want a higher-touch, protocol-driven peptide platform rather than a self-service marketplace, and who are willing to pay concierge-tier pricing for that experience. Best fit for patients using peptides across multiple categories (recovery, sleep, hormones) rather than for a single indication.

Launched publicly June 30, 2026. Co-founders Greg Yuna (CEO) and Gabriella Shak built Pep Club specifically around the peptide category with at-home biomarker testing as the differentiator.

The platform offers 12+ categories including weight management (GLP-1s), hormone optimization (testosterone, thyroid), sexual health (PT-141, sildenafil, tadalafil), hair restoration (finasteride, GHK-Cu, oral minoxidil), skin and acne (tretinoin, cosmetic peptides), IV and vitamin support, peptides (BPC-157, TB-500, ipamorelin, sermorelin among the compounded offerings), and longevity.

The key differentiator: at-home capillary biomarker testing. Patients submit a small blood sample from a near-painless collection device, and lab-quality panels come back to inform treatment personalization. Every protocol is reviewed and supervised by licensed clinicians and fulfilled through licensed pharmacy partners.

Who Pep Club is best for: patients who want data-driven peptide selection with lab work built into the platform, and who plan to use multiple peptide categories rather than just weight loss. As a new launch, the operational reputation is still being established.

A quick tour of the rest of the market.

Noom — Best known for weight-loss coaching. Acquired a compounding pharmacy in 2025 and now prescribes GLP-1s through the app. Strong on behavior change, less deep on peptide variety.

Sesame — Cash-pay marketplace that connects patients to individual physicians for one-off visits. Some Sesame doctors write GLP-1 prescriptions; the model is less integrated than the dedicated platforms.

Amaze — Compounded GLP-1 focus, similar to Henry Meds but smaller scale.

Ivim Health — Concierge-tier weight loss with individual physician management. Higher price point than mass-market platforms.

Push Health — Physician-owned platform where individual doctors set their own protocols; less consumer-facing branding than Hims or Ro.

Emerge, Fella Health, Mochi Health — Newer entrants each with slightly different niches (male-focused, women-focused, low-cost compounded).

The major differences at this tier: whether the platform is compounding-heavy or branded-heavy, whether it includes lab work, whether it has an app or is web-only, and whether physician time per patient is deep or shallow.

The framework, in short.

What is being prescribed. Is it FDA-approved branded product (Wegovy, Zepbound, Ozempic, Mounjaro, Foundayo) or a compounded preparation? Branded product has manufacturer quality control; compounded product depends on the specific pharmacy. Ask which pharmacy fills your prescription. A platform that will not answer that question is one to avoid.

Which pharmacy fills your prescription. Every 503A pharmacy in the US should comply with USP <795> and <797> standards, be state-board licensed, and ideally hold PCAB accreditation. A platform's pharmacy partner matters more than the platform's marketing.

How much physician contact you get. Some platforms are set up for a single intake visit followed by automatic monthly refills; others build in quarterly check-ins, lab work, and dose adjustments. If you want more clinical oversight (usually a good idea for GLP-1s given the side-effect profile), pick a platform that provides it.

Total cost per year. Membership fee plus medication plus lab fees plus shipping. Some platforms front-load with a low first-month price; others charge upfront but have lower monthly recurring costs. Calculate the annual cost, not the intro price.

Certificate of Analysis (COA) availability. For compounded peptides, ask if you can see a COA for the specific batch you receive. Reputable platforms will produce one on request.

Prescriber accountability. Is your prescribing physician's name on the prescription? Are they US-licensed? Are they on the FDA Preclusion List? All should be verifiable.

Three things are likely over the next 12 months.

First, the July 23-24 PCAC vote will reshape the non-GLP-1 peptide product mix. If the FDA accepts affirmative PCAC recommendations on any of the seven substances under review (BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, Epitalon), platforms will roll them out within 30-90 days. Hims, Pep Club, and NohoLabs are best positioned to capitalize because they already have peptide-category infrastructure.

Second, the FDA's proposed permanent exclusion of semaglutide, tirzepatide, and liraglutide from the 503B bulks list (comment window closed June 29, 2026) will finalize over the next several months. Once finalized, high-volume compounded GLP-1 supply through outsourcing facilities effectively ends. Patient-specific 503A compounding continues under narrow conditions. Henry Meds and other compounding-heavy platforms will need to shift business models.

Third, Sandoz's June 29 FDA acceptance of two generic tirzepatide abbreviated new drug applications starts the first-generic race. Approvals typically take 12-24 months. Once generic tirzepatide reaches the US market (probably 2027-2028), branded pricing pressure will grow, and telehealth platforms will need to renegotiate branded partnerships or shift toward generic supply.

For patients today: the platform choice depends more on your specific needs (weight loss only vs broader peptide portfolio, high-touch vs self-service, cost-sensitivity vs premium experience) than on any single platform being universally better. Use the evaluation framework above to match your priorities to the platform's actual offering. Ask the specific pharmacy sourcing question. And plan to reassess every 6 months as the regulatory picture keeps moving.